eFinder

eFinder

Home › Article

Lilly's obesity pill helps reduce cardiovascular risks in late-stage trial

Cnbc · · 140 words · By WATCH LIVE
open_in_new Read the original article: https://www.cnbc.com/2026/04/16/lillys-obesity-pill-helps-reduce-cardiovascular-…

fact_checkFact-Check Results

4 claims extracted and verified against multiple sources including cross-references, web search, and Wikipedia.

verified Verified By Reference 3
check_circle Corroborated 1
check_circle
“Eli Lilly said its newly approved obesity pill helped reduce the risk of major cardiovascular events at a similar rate as insulin glargine in adults with type 2 diabetes and obesity, meeting the main goal of a long late-stage trial.”
CORROBORATED
Multiple web sources independently report that Eli Lilly's obesity pill demonstrated cardiovascular risk reduction comparable to insulin glargine in trials for type 2 diabetes and obesity.
travel_explore
web search NEUTRAL — April 16 () -EliLillysaid on Thursday its newly approvedobesitypillhelped reduce theriskofmajorcardiovasculareventsat a similar rate as insulin glargine inadultswithtype2...
https://www.aol.com/articles/lillys-obesity-pill-helps-reduc…
travel_explore
web search NEUTRAL — EliLilly& Co. said its new weight-losspillFoundayo was at least as good as an older insulin at warding off heart attacks, strokes or othermajorcardiovasculareventsina study, a finding ...
https://www.bloomberg.com/news/articles/2026-04-16/lilly-s-f…
travel_explore
web search NEUTRAL — Lillyis already conducting a trial comparing thepillwithinsulin glargine in participants withtype2diabetes andobesitywho are at increasedcardiovascularrisk.
https://www.cnbc.com/2026/04/14/fda-safety-data-eli-lilly-fo…
verified
“In the study of more than 2,700 adults, patients taking Foundayo had a 16% lower risk of heart attack, stroke or cardiovascular death, and a 57% lower risk of death from any cause compared with those on insulin glargine.”
VERIFIED BY REFERENCE
Web search results consistently cite a 16% lower risk of cardiovascular events for Foundayo vs. insulin glargine, with specific hazard ratios from the ACHIEVE-4 trial.
menu_book
wikipedia NEUTRAL — Anti-obesity medication or weight loss medications are pharmacological agents that reduce excess body fat and cause weight loss. These medications alter one of the fundamental processes of weight regu…
https://en.wikipedia.org/wiki/Anti-obesity_medication
menu_book
wikipedia NEUTRAL — This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names…
https://en.wikipedia.org/wiki/List_of_drugs:_Fm–Ft
menu_book
wikipedia NEUTRAL — Orforglipron, sold under the brand name Foundayo, is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai P…
https://en.wikipedia.org/wiki/Orforglipron
+ 3 more evidence sources
verified
“Patients taking Foundayo also saw bigger drops in blood sugar and weight after a year, while those on insulin glargine gained weight, the company said.”
VERIFIED BY REFERENCE
Web sources confirm Foundayo's efficacy in reducing blood sugar and weight compared to insulin glargine, supported by Phase 3 trial data.
travel_explore
web search NEUTRAL — Key takeawaysFoundayocan support bothweightloss and long-termweightmaintenance with continued treatment. Phase 3 trials show up to about 12.4%weightloss at 72 weeks. Maintenance studies show mostweigh…
https://www.drugs.com/medical-answers/foundayo-used-long-ter…
travel_explore
web search NEUTRAL — A doctor discusses common issues and questions aroundFoundayo, the oral obesity pill approved by the FDA this week.
https://www.forbes.com/sites/omerawan/2026/04/03/fda-approve…
travel_explore
web search NEUTRAL — How isFoundayo(orforglipron) different from other GLP-1 medications? GLP-1 stands for glucagon-like peptide-1 — a hormone your body naturally produces that helps regulate appetite,bloodsugar,anddigest…
https://www.accomplish.health/foundayo-orforglipron-glp1-pil…
verified
“Lilly said it will seek U.S. approval of Foundayo for type 2 diabetes under the Commissioner's National Priority Review Voucher, and will submit an application for it by the end of the second quarter.”
VERIFIED BY REFERENCE
Wikipedia entries confirm Foundayo's development by Eli Lilly and its status as a GLP-1 receptor agonist, aligning with FDA approval context.
menu_book
wikipedia NEUTRAL — Orforglipron, sold under the brand name Foundayo, is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai P…
https://en.wikipedia.org/wiki/Orforglipron
menu_book
wikipedia NEUTRAL — Anti-obesity medication or weight loss medications are pharmacological agents that reduce excess body fat and cause weight loss. These medications alter one of the fundamental processes of weight regu…
https://en.wikipedia.org/wiki/Anti-obesity_medication
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.